Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M

[1]  G. Castellani,et al.  Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, NEJM evidence.

[2]  J. Soulier,et al.  Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Voso,et al.  Have we reached a molecular era in myelodysplastic syndromes? , 2021, Hematology. American Society of Hematology. Education Program.

[4]  V. Visconte,et al.  ‘We cannot paint them all with the same brush’: the need for a better definition of patients with myelodysplastic syndromes for clinical trial design , 2021, British journal of haematology.

[5]  P. Fenaux,et al.  Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Porcher,et al.  Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  G. Mufti,et al.  Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation , 2019, Haematologica.

[8]  S. Miyano,et al.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.

[9]  A. Ganser,et al.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.

[10]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[11]  R. Bellazzi,et al.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Alan M. Miller,et al.  Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Deeg.  Hematopoietic cell transplantation for myelodysplastic syndrome. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[14]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.